GlassScriptPhysician profile
Jackie Posvar
NPI 1952768194
$1,474.68
in general payments reported to CMS, 2019-2025
26 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9.43 · 2022: $93.07 · 2023: $275 · 2024: $824 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $328.14 | 2022-2024 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $188.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $110.47 | 2024-2025 | |
| Daiichi Sankyo INC. | $88.10 | 2022-2024 | Injectafer |
| Abbott Laboratories | $87.13 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $72.83 | 2024-2025 | Zepbound, Jardiance |
| Exact Sciences Corporation | $70.81 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $61.21 | 2022-2024 | |
| Shield Therapeutics INC | $60.81 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.62 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $44.25 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $34.04 | 2023-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $32.14 | 2024 | |
| Glaxosmithkline, LLC. | $29.10 | 2023-2024 | Shingrix, Arexvy |
| Biogen, INC. | $24.37 | 2024 | Spinraza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $21.74 | 2023 | Nexletol |
| Edwards Lifesciences Corporation | $21.17 | 2022 | |
| Hologic Sales and Service, LLC | $19.96 | 2025 | Thinprep 2000 Processor, Aptima |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.28 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $18.89 | 2023 | Nuedexta |
| Currax Pharmaceuticals LLC | $16.52 | 2023 | Contrave, Onzetra Xsail |
| Radius Health, INC. | $16.34 | 2025 | Tymlos |
| Merck Sharp & Dohme LLC | $16.20 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $15.38 | 2025 | |
| Amgen INC. | $13.77 | 2025 | Repatha, Otezla |
| Genentech USA, INC. | $9.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Posvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.